1. Academic Validation
  2. Cryptochlorogenic acid and its metabolites ameliorate myocardial hypertrophy through a HIF1α-related pathway

Cryptochlorogenic acid and its metabolites ameliorate myocardial hypertrophy through a HIF1α-related pathway

  • Food Funct. 2022 Feb 21;13(4):2269-2282. doi: 10.1039/d1fo03838a.
Jie Li 1 Xiaohe Chen 1 Xiang Li 1 Jiayang Tang 2 Yan Li 1 Bin Liu 1 Shuzhen Guo 2
Affiliations

Affiliations

  • 1 School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488, PR China. liubinyn67@163.com.
  • 2 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, PR China. guoshz@bucm.edu.cn.
Abstract

Cryptochlorogenic acid (4-CQA) is a phenolic acid that has antioxidant and anti-inflammatory activities. Our preliminary study found that 4-CQA has a good effect on isoproterenol (ISO)-induced myocardial hypertrophy, while the mechanism remains largely unknown. This study aimed at delineating the metabolites and metabolic pathways of 4-CQA using liquid mass spectrometry and molecular biotechnology, exploring possible active metabolites and the mechanism of myocardial hypertrophy amelioration in H9c2 cells, and finally, investigating the pharmacokinetics of 4-CQA and its active metabolites in vivo. In summary, 56 potential effective metabolites were distinguished in rat urine, feces, plasma samples and heart tissue after intragastric administration of 4-CQA, and the main metabolic reaction types of 4-CQA included hydrogenation, methylation, glucuronidation, sulfation, hydration and their composite reactions in in vivo biotransformation. Besides, 4-CQA and its main active metabolites, caffeic acid and 4-O-feruloylquinic acid, significantly ameliorated pathological cardiac hypertrophy of H9c2 cells treated with ISO based on the Akt/mTOR/HIF-1α pathway. In addition, this study demonstrated that the prototype drugs 4-CQA and 4-O-ferulylquinic acid generally exhibit similar pharmacokinetic characteristics and caffeic acid presents relatively late peak time and low peak concentration in rats, which make them suitable candidate drugs.

Figures
Products